-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
CNS Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2018 to Q3 2024.
- CNS Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$5.63M, a 24.2% decline year-over-year.
- CNS Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$17.1M, a 8.27% increase year-over-year.
- CNS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$18.9M, a 23.6% decline from 2022.
- CNS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$15.3M, a 5.39% decline from 2021.
- CNS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$14.5M, a 53.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)